Solomon Moshkevich Sells 1,013 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,013 shares of Natera stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total value of $243,656.89. Following the transaction, the insider owned 143,686 shares of the company’s stock, valued at approximately $34,560,793.58. This represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.

Natera Stock Down 0.1%

NASDAQ:NTRA opened at $231.14 on Friday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock’s 50-day moving average price is $235.91 and its 200-day moving average price is $193.80. The stock has a market capitalization of $31.97 billion, a PE ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.26) EPS. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Analysts Set New Price Targets

Several equities analysts have issued reports on NTRA shares. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a report on Monday, January 12th. Guggenheim upped their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price objective on the stock in a report on Monday, October 27th. Wells Fargo & Company boosted their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, Citigroup initiated coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC boosted its holdings in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC lifted its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its position in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Natera during the second quarter worth $298,000. Finally, Signaturefd LLC grew its holdings in Natera by 10.0% in the 2nd quarter. Signaturefd LLC now owns 1,620 shares of the medical research company’s stock valued at $274,000 after buying an additional 147 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.